DAX25.092 -0,3%Est506.055 -0,3%MSCI World4.343 -0,1%Top 10 Crypto9,5000 -2,5%Nas26.917 +0,9%Bitcoin63.278 -1,0%Euro1,1653 +0,2%Öl93,31 -1,8%Gold4.495 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Infineon 623100 NVIDIA 918422 Micron Technology 869020 Siemens Energy ENER6Y SAP 716460 NEL ASA A0B733 RENK RENK73 Deutsche Bank 514000 Plug Power A1JA81 Lufthansa 823212 Deutsche Telekom 555750 adidas A1EWWW AMD (Advanced Micro Devices) 863186 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Angriffe auf Iran: DAX verliert letztlich -- Wall Street schließt grün -- Salesforce enttäuscht mit Gewinn -- Micron, ServiceNow, Snowflake, Rheinmetall, OHB, AMD, Microsoft, Dell, Bitcoin im Fokus
Top News
Marvell-Aktie erholen sich von Fall: Starker Ausblick reicht nach Rally von 130 Prozent nicht Marvell-Aktie erholen sich von Fall: Starker Ausblick reicht nach Rally von 130 Prozent nicht
Micron-Aktie jagt von Rekord zu Rekord: Bewertung spricht für die Bullen Micron-Aktie jagt von Rekord zu Rekord: Bewertung spricht für die Bullen
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

REGENXBIO Aktie

Kaufen
Verkaufen
REGENXBIO Aktien-Sparplan
5,91 EUR +0,20 EUR +3,58 %
BMN
6,88 USD +0,19 USD +2,84 %
BTT
finanzen.net zero
REGENXBIO jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.281,05 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA140E0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75901B1070

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRGNX

REGENXBIO Aktien News

DatumMeistgelesen
PR NewswireREGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
PR NewswireREGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR NewswireREGENXBIO to Participate in Upcoming Investor Conference
Wer­bungREGENXBIO-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireREGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
PR NewswireREGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
PR NewswireREGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
PR NewswireREGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
PR NewswireREGENXBIO Announces Presentation at the World Muscle Society
PR NewswireREGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
PR NewswireREGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
PR NewswireREGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
PR NewswireREGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
PR NewswireREGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
PR NewswireREGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
PR NewswireREGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
PR NewswireREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
PR NewswireFDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
PR NewswireREGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
PR NewswireREGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
PR NewswireREGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
PR NewswireREGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
PR NewswireREGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
PR NewswireREGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
PR NewswireREGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
PR NewswireAbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
PR NewswireApollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PR NewswireREGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
PR NewswireREGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
PR NewswireREGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO News

REGENXBIO News: auf dieser Seite finden Sie alle REGENXBIO News und Nachrichten zur REGENXBIO Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch REGENXBIO News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um REGENXBIO News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.